Belt and Road Summit 2025- Deal-making

10–16 Sept 2025 | China (Hong Kong)

ProjectUpdated on 2 August 2025

Liver-in-Cube

Jiang Liu

Research Assistant Professor at Oncoimmunostics Limited

Hong Kong, China (Hong Kong)

About

"Liver-in-Cube”- the world's first 3D-bioprinted biomimetic liver cancer precision theranostic platform, precisely reconstructs the liver cancer microenvironment using patient-derived cells and extracellular matrix. The platform creates personalized “patient avatars” for drug screening that significantly improves the prediction accuracy of drug response rate. This platform overcomes the limitations of empirical animal model and organoid by providing a highly biomimetic, standardized, and high-throughput solution for drug efficacy and pharmacokinetic assessment, shortening R&D cycles and increasing clinical trial success rates. The technology is expanding into a comprehensive precision oncology theranostic system, poised to become the gold standard in cancer standard of care and establish a new paradigm in precision cancer therapy.

Project Location

  • China (Hong Kong)

Project Format

  • Public-Private Partnership Project

ESG (Environmental, Social, and Governance)

  • No

Project Stage

  • Operations

Main Project Sector

  • Technology

Technology

  • Bio-Tech
  • Health Technology
  • Medical Technology

Total Project Value

  • 10,000,001 to 25,000,000 USD

Investment Capital Required

  • 5,000,001 to 7,500,000 USD

Interested Format of Cooperation

  • Open for Negotiation
  • R&D Cooperation

Preferred Financing Model

  • Open for negotiation

Previous Funding Stage

  • Seed & Pre-Series

Main Service(s) Required

  • Financial Services
  • Professional Services

Financial Services

  • Private Equity & Venture Capital
  • Risk Management (Financial Services)

Professional Services

  • Business Valuation
  • Consultancy
  • Financial Advisory
  • IP Related
  • Risk Management

Organisation

Oncoimmunostics Limited

Hong Kong, China (Hong Kong)

Similar opportunities

  • Project

    Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)

    • Yes
    • Equity
    • Bio-Tech
    • Technology
    • Joint Venture
    • Private Project
    • R&D Cooperation
    • Seed & Pre-Series
    • Financial Services
    • Business Valuation
    • Corporate Services
    • Open for Negotiation
    • Open for negotiation
    • Professional Services
    • Minority Shareholdings
    • Institutional Investment
    • Feasibility Study Completed
    • Market Entry Strategic Analysis
    • Private Equity & Venture Capital

    Haiyang Wang

    CEO at Shanghai Haiju Biotechnology Co., Ltd.

    Shanghai, China

  • Project

    Prohep: Innovative Microbial Therapy for Liver Health and Cancer Prevention

    • Yes
    • Operations
    • Technology
    • Seed & Pre-Series
    • Medical Technology
    • Professional Services
    • Public-Private Partnership Project

    Terence Hung

    Director at Anverio ESG Consulting

    Hong Kong, China (Hong Kong)

  • Project

    Single Cell Drug Screening AI Platform

    • Yes
    • None
    • Equity
    • Bio-Tech
    • Technology
    • Private Project
    • R&D Cooperation
    • Open for negotiation
    • Professional Services
    • Minority Shareholdings
    • 2,500,001 to 5,000,000 USD
    • 1,000,001 to 2,500,000 USD
    • Feasibility Study Completed
    • Public–private partnership / Concession

    Marco Suen

    Founder & CEO at Provectus Therapeutics Limited

    Hong Kong, China (Hong Kong)